A Cost-Effectiveness Analysis of Telaprevir Versus Boceprevir in the Treatment of Hepatitis C: a Greek National Health System Perspective

Trial Profile

A Cost-Effectiveness Analysis of Telaprevir Versus Boceprevir in the Treatment of Hepatitis C: a Greek National Health System Perspective

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 May 2015

At a glance

  • Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ADVANCE; REALIZE; RESPOND-2; SPRINT-2
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 14 Nov 2012 New trial record
    • 07 Nov 2012 Results presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top